 |
|
|
The Top 10 Generics Companies: Strategic insight, growth opportunities and competitive dynamics in the US and Europe
|
|
|
|
|
| Description: |
The generics sector has grown at a fast pace over the past few years, outperforming the pharmaceutical market as a whole; generic growth opportunities are significant, with an estimated $100bn worth of branded pharmaceutical products to go off patent by 2010, of which $21bn expire in 2006. Although US and major European generic drug sales increased rapidly from 2000 to 2003, there has been a slowdown in growth during 2004. In response to an increasingly competitive unbranded generic pharmaceutical marketplace, and a slowdown in growth in 2004, some of the major generics players have consolidated. The two largest M&A deals in the generics market in recent years have been the acquisition of Eon and HEXAL Labs by Sandoz in February 2005, and the acquisition of IVAX by Teva in January 2006. 'The Top 10 Generics Companies: Strategic insight, growth opportunities and competitive dynamics in the US and Europe', identifies the successful strategies utilized by the industry’s key players in the US and Western European market. The report provides insights into the top 10 generic companies strengths, weaknesses, opportunities and threats in the generic pharmaceutical market, allowing you to tailor the best practice strategies of the generic industry’s leading players to your company’s needs. |
|
| |
|
|
| Source: |
Business Insights |
|
| Type: |
Report |
|
| Doc Number: |
RBHC0152 |
|
| Format: |
PDF |
|
| Pages: |
178 |
|
| Publication
Date: |
Mar-06 |
|
| Price: |
US$
2,875 |
|
 |
Table of Contents >> |
|
 |
To order the complete report,
please call: 610.356.1067 |
|
|
Public
Feeds 
